Raynaud’s Phenomenon

  • Ariane L. Herrick

Case Report

A 38-year-old female patient presented to the rheumatology clinic with a 3-week history of a painful fingertip ulcer. The pain was so severe that it was keeping her awake at night. For 20 years (since her teens) her hands had been turning white then purple in the cold weather, going red (with tingling) when rewarming. Her feet also felt cold. Her family doctor had told her that this was Raynaud’s phenomenon, which was very common. However, each winter her symptoms seemed to be worsening, and even a slight temperature change would bring on an attack. The previous winter she had had some finger ulcers which had, however, been less painful than the current one and which had healed spontaneously. Also of concern to her was that for 6 months the skin of her fingers had felt tight, and she had recently been experiencing some difficulty swallowing, with heartburn. There was no past medical history of note. She had smoked five cigarettes a day for 2 years. There was no history of...


  1. 1.
    LeRoy EC, Medsger TA. Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol. 1992;10:485–8.PubMedGoogle Scholar
  2. 2.
    Herrick AL. Pathogenesis of Raynaud’s phenomenon. Rheumatology. 2005;44:587–96.CrossRefPubMedGoogle Scholar
  3. 3.
    Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum. 1975;4:351–68.CrossRefPubMedGoogle Scholar
  4. 4.
    Maricq HR, LeRoy EC. Patterns of finger capillary abnormalities in connective tissue disease by “wide-field” microscopy. Arthritis Rheum. 1973;16:619–28.CrossRefPubMedGoogle Scholar
  5. 5.
    Harvey GR, McHugh NJ. Serologic abnormalities in systemic sclerosis. Curr Opin Rheumatol. 1999;11:495–502.CrossRefPubMedGoogle Scholar
  6. 6.
    LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.PubMedGoogle Scholar
  7. 7.
    Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ. Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum. 1992;35:688–93.CrossRefPubMedGoogle Scholar
  8. 8.
    Harrison BJ, Silman AJ, Hider SL, Herrick AL. Cigarette smoking: a significant risk factor for digital vascular diseases in patients with systemic sclerosis. Arthritis Rheum. 2002;46:3312–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44:1841–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Herrick AL. Treatment of Raynaud’s phenomenon – update, new insights and developments. Curr Rheumatol Rep. 2003;5:168–74.CrossRefPubMedGoogle Scholar
  11. 11.
    Raynaud’s Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med. 2000;160:1101–8.CrossRefGoogle Scholar
  12. 12.
    Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994;120:199–206.CrossRefPubMedGoogle Scholar
  13. 13.
    Tomaino MM, Goitz RJ, Medsger TA. Surgery for ischemic pain and Raynaud’s phenomenon in scleroderma: a description of treatment protocol and evaluation of results. Microsurgery. 2001;21:75–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Ho M, Veale D, Eastmond C, Nuki G, Belch J. Macrovascular disease and systemic sclerosis. Ann Rheum Dis. 2000;59:39–43.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Rheumatic Diseases CentreUniversity of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation TrustSalfordUK

Personalised recommendations